STERIS plc $STE Shares Sold by US Bancorp DE

US Bancorp DE lessened its holdings in shares of STERIS plc (NYSE:STE) by 15.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,086 shares of the medical equipment provider’s stock after selling 2,416 shares during the quarter. US Bancorp DE’s holdings in STERIS were worth $3,238,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Colonial Trust Co SC boosted its position in STERIS by 0.3% in the 3rd quarter. Colonial Trust Co SC now owns 12,329 shares of the medical equipment provider’s stock valued at $3,051,000 after buying an additional 42 shares during the period. Allworth Financial LP raised its stake in shares of STERIS by 7.3% in the second quarter. Allworth Financial LP now owns 661 shares of the medical equipment provider’s stock valued at $159,000 after acquiring an additional 45 shares in the last quarter. Geneos Wealth Management Inc. boosted its holdings in STERIS by 34.9% in the second quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 45 shares during the period. Fifth Third Bancorp grew its stake in STERIS by 1.6% during the 3rd quarter. Fifth Third Bancorp now owns 2,953 shares of the medical equipment provider’s stock worth $731,000 after purchasing an additional 46 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. grew its stake in STERIS by 1.4% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,494 shares of the medical equipment provider’s stock worth $865,000 after purchasing an additional 48 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Stock Down 1.8%

STE stock opened at $243.24 on Wednesday. The stock has a market cap of $23.85 billion, a P/E ratio of 33.92 and a beta of 1.05. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. STERIS plc has a twelve month low of $204.90 and a twelve month high of $269.44. The company’s 50 day moving average is $255.46 and its two-hundred day moving average is $251.76.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. During the same period in the prior year, the business posted $2.32 EPS. STERIS’s revenue was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Research analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Tuesday, February 17th will be given a $0.63 dividend. The ex-dividend date of this dividend is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. STERIS’s dividend payout ratio is 35.15%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on STE. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $275.20.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.